Glass House Brands (GLAS) Short term Debt (2020 - 2021)
Glass House Brands' (GLAS) quarterly Short term Debt came in at $4.6 million in Q1 2021, up 1219.78% on a QoQ basis from $349034.0 in Q4 2020.
Glass House Brands (GLAS) Short term Debt (2020 - 2021) Analysis & Trends
Glass House Brands (GLAS) has 2 years of Short term Debt data on file, last reported at $4.6 million in Q1 2021.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $4.6 million in Q1 2021; TTM through Mar 2021 was $4.6 million, a N/A change from a year earlier, with the FY2020 full-year figure at $349034.0, changed N/A from the prior year.
- Short term Debt for Q1 2021 stood at $4.6 million, up from $349034.0 in the prior quarter.
- Over the last five years, Short term Debt for GLAS reached as high as $4.6 million in Q1 2021 and fell as low as $349034.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 4.61 Mn |
| Dec 31, 2020 | 349,034.00 |